National Institute for Health and Care Excellence5d
In consultation: Guidance and quality standards
Health inequalities modular update to NICE health technology evaluations: the manual (PMG36) Methods / process manual consultation NICE process and methods 31 January 2025 Highly specialised ...
National Institute for Health and Care Excellence6d
Published: Guidance, quality standards and advice
Elranatamab for treating relapsed and refractory multiple myeloma after 3 or more treatments TA1023 11 December 2024 11 December 2024 ...
National Institute for Health and Care Excellence6d
Savolitinib with durvalumab for treating MET-driven unresectable advanced papillary renal cell carcinoma [ID6520]
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in ...
National Institute for Health and Care Excellence6d
Avatrombopag for treating primary chronic immune thrombocytopenia in people 1 to 17 years [TSID 12109]
Further information The NICE-Wide Prioritisation Board and NHS England have agreed that a Technology Appraisal (TA) would not be appropriate for this product and recommended that it is not selected ...
National Institute for Health and Care Excellence7d
NICE Health Technology Assessment training programme
have completed their Master of Public health (MPH) or individuals undertaking the portfolio route must have either passed their DFPH (Faculty of Public Health Diplomate Examination, formally Part A ...